"These compelling results strengthen the rationale for combining MP-470 with DNA-damaging agents due to MP-470's purported ability to suppress the Rad51 DNA repair mechanism, which is important in various malignancies," said Dr. Gregory Berk, SuperGen's Chief Medical Officer. "We look forward to presenting updated results on MP-470 in combination with these platinum doublets, as well as the other three standard of care arms of the trial in the future."
Earlier this year, U.S. Food and Drug Administration granted orphan drug designation for MP-470 in the treatment of glioblastoma multiforme (GBM) after non-clinical studies showed more than two-fold effect of increased cell death when used synergistically with ionizing radiation. Orphan drug designation for GBM, an often fatal form of brain cancer, can entitle SuperGen to seven years of market exclusivity. SuperGen's lead product candidate has also shown promise in preclinical testing across a wide spectrum of cancers, including non-small cell lung cancer.
Furthermore, SuperGen presented four additional posters at the
Symposium that reviewed clinical and non-clinical advances of the compounds
MP-470, SGI-1776 and SGI-1252. These include:
Abstract 332: In vivo activity of SGI-1776, an orally active PIM kinase
Abstract 426: Effects of food on the single-dose pharmacokinetics of oral
Abstract 480: MP-470, a novel multi-targeted tyrosine kinase inhibitor
targeting Rad51 is not toxic to human primary marrow stem cells at
clinically relevant concentrations
Abstract 571: Modulation of JAK2 signaling pathways in vitro and in vivo
Copies of the 20th EORTC-NCI-AACR Symposium poster presentations wil
|SOURCE SuperGen, Inc.|
Copyright©2008 PR Newswire.
All rights reserved